Skip to content
DataLookout
Menu

NCT07907406

Comparison Between Efficacy of Gabapentin and Carbamazepine in Neuropathic Pain of Guillain-Barré Syndrome Patients

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Mean neuropathic pain score
Timeframe: Baseline and 7 day after initiation of treatment.

Arms and interventions

Group A-GabapentinExperimental

Patients received gabapentin 300 mg three times daily for seven days after plasma exchange for Guillain-Barré syndrome.

Group B-CarbamazepineActive comparator

Patients received carbamazepine 100 mg three times daily after plasma exchange

Drugs: Gabapentin, Carbamazepine

Sites

1 site in 1 country

  • Lahore General Hospital, LahoreLahore, Punjab Province, Pakistan